| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $69,946,948 ) (Continued on the next page) |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01EB034757 | Low-dose contrast enhanced fast pediatric brain MRI | 000 | 3 | NIH | 3/27/2026 | $588,069 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R35HL166556 | Inflammation and thrombosis fuel cardiovascular and pulmonary disease: Focus on the interplay of neutrophil inflammasomes with NETs | 000 | 4 | NIH | 3/2/2026 | $1,177,050 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS121657 | Motion and Distortion Robust Diffusion Weighted Imaging Sequences for Pediatric Patients | 001 | 4 | NIH | 2/26/2026 | $44,250 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS140165 | Use-Dependent Adjustments to Dopamine Reception in Motivational Control | 001 | 2 | NIH | 2/26/2026 | $53,686 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS112343 | Development of Specific Neuron-Glia Attachments | 001 | 7 | NIH | 2/24/2026 | $58,088 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS129823 | Targeting the Choroid Plexus-Cerebrospinal Fluid System to Treat Post-Hemorrhagic Hydrocephalus | 001 | 4 | NIH | 2/24/2026 | $58,279 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R21AI178693 | Candida albicans Target of Rapamycin in oxidative stress responses | 000 | 2 | NIH | 11/26/2025 | $222,500 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R00NS119743 | Precision Base Editing for the Treatment of Motor Neuron Diseases | 001 | 5 | NIH | 2/24/2026 | $24,899 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U01AI125051 | Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector | 000 | 9 | NIH | 1/7/2026 | $828,518 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | UH3NS132144 | Detection and Characterization of Somatic Mutations in Human Tissue Utilizing Duplex-Consensus Sequencing | 000 | 4 | NIH | 2/25/2026 | $711,998 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01MH129636 | Predicting psychosis risk in youth using a novel structural neuroimaging score that measures deviation from normative development. Can we bring it to communities using portable, low-field MRI? | 000 | 5 | NIH | 2/24/2026 | $749,537 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS120986 | Predicting ASD and Other Developmental Outcomes in the First Year of Life Using EEG in a Diverse Community-Based Sample | 001 | 5 | NIH | 3/2/2026 | $126,544 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD116750 | Understanding the mechanism of pre- to naïve- to formative- pluripotency transitions | 000 | 2 | NIH | 1/13/2026 | $684,556 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K23EY034212 | Spatial Frequency Dependent Deficits in Anisometropic Amblyopia | 000 | 4 | NIH | 1/12/2026 | $142,669 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K23NS140397 | Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis | 000 | 2 | NIH | 1/8/2026 | $229,407 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD110772 | Accurate, reliable, and interpretable machine learning for assessment of neonatal and pediatric brain micro-structure | 000 | 4 | NIH | 1/13/2026 | $342,495 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS121334 | Fetal Brain MRI as a Predictor of Late Neurodevelopmental Outcome in Congenital Heart Disease | 000 | 5 | NIH | 12/24/2025 | $396,666 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS142815 | Dissecting Neural Circuits for Top-Down Control of Sympathetic Functions | 000 | 1 | NIH | 1/15/2026 | $674,950 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K08NS130150 | The Role of Fos and the BAF Complex in Neuronal Activity-Dependent Chromatin Remodeling and Gene Expression | 000 | 4 | NIH | 4/9/2026 | $192,020 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI181618 | HIV-1 membrane fusion and inhibition | 000 | 3 | NIH | 3/30/2026 | $752,675 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL096384 | Blood vessel assembly from multipotent hemangioma-derived stem cells | 000 | 15 | NIH | 4/2/2026 | $704,496 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI197972 | A multi-biologic, AAV-deliverable HIV-1 functional cure | 000 | 1 | NIH | 4/1/2026 | $889,519 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01DE033701 | Architecture and function of the neural crest genome | 000 | 3 | NIH | 4/2/2026 | $554,035 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | F32AI186297 | Understanding the role of transmembrane proteins for Plasmodium cell division | 001 | 2 | NIH | 4/2/2026 | $1,260 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R37AI077595 | Mechanisms that Regulate Antibody Class Switch Recombination and Somatic Hypermutation | 000 | 18 | NIH | 4/1/2026 | $637,200 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI189789 | Molecular mechanism of tetanus neurotoxin pathogenesis | 000 | 2 | NIH | 4/1/2026 | $833,213 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL167925 | Simple and Effective Laceration of Potentially-calcified Leaflets as an Adjunct to Transcatheter Valve Replacement | 001 | 3 | NIH | 3/13/2026 | $23,670 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01CA287076 | Activating gasdermin pores to induce pyroptosis and stimulate anti-tumor immunity | 000 | 3 | NIH | 4/1/2026 | $733,069 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD112379 | Metabolic control of the neural crest epigenome | 001 | 3 | NIH | 4/2/2026 | $56,054 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI139087 | Structure and Function of C. Difficile Toxins | 000 | 6 | NIH | 4/1/2026 | $3,307,473 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL146128 | MSC Exosome Treatment for BPD: Impact on Immunity and Lung Development | 000 | 8 | NIH | 3/23/2026 | $867,215 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K08HL173561 | Endothelial cell-based therapy for pulmonary vascular disease using induced pluripotent stem cells | 000 | 3 | NIH | 3/24/2026 | $167,940 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL158192 | High resolution lineage tracing of developmental hematopoiesis | 001 | 4 | NIH | 3/24/2026 | $22,059 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS134948 | Paradoxical Sensory Responses: A Clue Towards Understanding Biotypes in Autism Spectrum Disorder and Other Neurodevelopmental Disorders | 000 | 3 | NIH | 3/24/2026 | $461,954 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL178815 | Intravenous oxygen for the treatment of cardiac arrest | 000 | 2 | NIH | 3/24/2026 | $859,295 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL161605 | Glypicans in Bacterial Lung Infection | 000 | 3 | NIH | 3/27/2026 | $611,385 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01MH130356 | Effects of 16p11.2 copy number variation on neuronal development and pathology | 000 | 4 | NIH | 3/24/2026 | $813,612 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R35HL150876 | Cell-cell interactions governing lung epithelial progenitor cells | 001 | 7 | NIH | 3/25/2026 | $26,550 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | UH3NS132138 | Development of an Efficient High Throughput Technique for the Identification of High-Impact Non-Coding Somatic Variants Across Multiple Tissue Types | 000 | 4 | NIH | 3/30/2026 | $674,029 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K08AR080992 | Development of resident memory T cells in the synovium | 000 | 5 | NIH | 3/23/2026 | $173,340 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL163513 | High-throughput Phenotyping of iPSC-derived Airway Epithelium by Multiscale Machine Learning Microscopy | 001 | 4 | NIH | 3/25/2026 | $23,409 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R21OD037909 | A modular system for murine CRISPR genome and epigenome editing | 000 | 2 | NIH | 3/27/2026 | $202,920 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | T2331594 | Children's Hospitals Graduate Medical Education Payment Program | 10 | 8 | HRSA | 3/17/2026 | $920,700 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | T2331594 | Children's Hospitals Graduate Medical Education Payment Program | 10 | 8 | HRSA | 3/17/2026 | $2,058,204 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U01AI152033 | Genetic and microbial modifiers of Atopic Dermatitis (AD): Mechanisms of increased AD severity in patients with the R576 polymorphism in IL-4Ra and impact of S aureus skin decolonization on AD | 000 | 7 | NIH | 4/3/2026 | $525,764 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HG012871 | An ensemble framework for regulatory variant prediction. | 000 | 4 | NIH | 4/3/2026 | $506,574 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | F32AI189235 | Antiretroviral mechanisms of TRIM56 | 001 | 2 | NIH | 4/3/2026 | $1,308 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD116750 | Understanding the mechanism of pre- to naïve- to formative- pluripotency transitions | 001 | 2 | NIH | 3/27/2026 | $76,061 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01DK142931 | Genomically-driven discovery of pediatric steroid sensitive nephrotic syndrome. | 000 | 1 | NIH | 1/22/2026 | $893,823 |
|
